ArticleBMC medicine2024
Microbiome-derived metabolites in early to mid-pregnancy and risk of gestational diabetes: a metabolome-wide association study.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Early pregnancy metabolomic signatures for child growth trajectories: a prospective metabolome-wide association study.The American journal of clinical nutrition · 2026Article
- A three-metabolite microbiota-associated signature for early risk stratification of gestational diabetes mellitus.Cardiovascular diabetology · 2026Article
- Maternal and infant gut microbiome.iMeta · 2026Review
- Advancing Personalized Medicine in Gestational Diabetes Mellitus Management Through Gut Microbiota Insights.International journal of molecular sciences · 2026Review
- Gestational diabetes mellitus and maternal-infant microbiome axis: mechanistic insights and therapeutic interventions.Journal of translational medicine · 2026Review
- Integrative analysis of placental metabolic reprogramming and microbiome alterations in gestational diabetes mellitus (GDM).Acta diabetologica · 2026Review
- Lifestyles, metabolome and diabetic kidney disease: a cohort study.QJM : monthly journal of the Association of Physicians · 2026Article
- LASSO regression-derived first-trimester (9-14Archives of gynecology and obstetrics · 2026Article
- The Placenta in Gestational Diabetes: An Integrated Review on Metabolic Pathways, Genetic, Epigenetic and Ultrasound Biomarkers for Clinical Perspectives.International journal of molecular sciences · 2026Review
- Gut-placenta axis: gut microbiota metabolites may play a role in regulating maternal-fetal immune tolerance and the pathogenesis of adverse pregnancy outcomes.Frontiers in immunology · 2026Review
- Gut microbiota contributes to gestational diabetes mellitus by interfering with bile acid metabolism and resistin.Frontiers in cellular and infection microbiology · 2026Article
- The interplay between gut microbiota and gestational diabetes mellitus: mechanisms, characteristics, and intervention strategies.Frontiers in microbiology · 2026Review
- Precision integrated identification of predictive first-trimester metabolomics signatures for early detection of gestational diabetes mellitus.Cardiovascular diabetology · 2025Article
- Unraveling the role of the gut microbiome in pregnancy disorders: insights and implications.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPre-diagnostic disturbances in the microbiome-derived metabolome have been associated with an increased risk of diabetes in non-pregnant populations. However, the roles of microbiome-derived metabolites, the end-products of microbial metabolism, in gestational diabetes (GDM) remain understudied. We examined the prospective association of microbiome-derived metabolites in early to mid-pregnancy with GDM risk in a diverse population.
methodsWe conducted a prospective discovery and validation study, including a case-control sample of 91 GDM and 180 non-GDM individuals within the multi-racial/ethnic The Pregnancy Environment and Lifestyle Study (PETALS) as the discovery set, a random sample from the PETALS (42 GDM, 372 non-GDM) as validation set 1, and a case-control sample (35 GDM, 70 non-GDM) from the Gestational Weight Gain and Optimal Wellness randomized controlled trial as validation set 2. We measured untargeted fasting serum metabolomics at gestational weeks (GW) 10-13 and 16-19 by gas chromatography/time-of-flight mass spectrometry (TOF-MS), liquid chromatography (LC)/quadrupole TOF-MS, and hydrophilic interaction LC/quadrupole TOF-MS. GDM was diagnosed using the 3-h, 100-g oral glucose tolerance test according to the Carpenter-Coustan criteria around GW 24-28.
resultsAmong 1362 annotated compounds, we identified 140 of gut microbiome metabolism origin. Multivariate enrichment analysis illustrated that carbocyclic acids and branched-chain amino acid clusters at GW 10-13 and the unsaturated fatty acids cluster at GW 16-19 were positively associated with GDM risk (FDR < 0.05). At GW 10-13, the prediction model that combined conventional risk factors and LASSO-selected microbiome-derived metabolites significantly outperformed the model with only conventional risk factors including fasting glucose (discovery AUC: 0.884 vs. 0.691; validation 1: 0.945 vs. 0.731; validation 2: 0.987 vs. 0.717; all P < 0.01). At GW 16-19, similar results were observed (discovery AUC: 0.802 vs. 0.691, P < 0.01; validation 1: 0.826 vs. 0.780; P = 0.10).
conclusionsDysbiosis in microbiome-derived metabolites is present early in pregnancy among individuals progressing to GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.